Top Markets
#1 Black Phoenix Black Phoenix +354.04%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +73.69%
#4 Gold Park Gold Park +58.04%
#5 Acurast Acurast +39.30%
#6 OpenEden OpenEden +35.14%
#7 BasedHype BasedHype +27.14%
#8 Cryptopia Cryptopia +21.54%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +21.45%
#10 Avantis Avantis +17.76%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Scandion Oncology A/S Scandion Oncology A/S

Scandion Oncology A/S

SCOL
Rank in Stocks #40631
Operating as a clinical-stage biotechnology company, Scandion Oncology A/S... Operating as a clinical-stage biotechnology company, Scandion Oncology A/S specializes in creating pharmaceutical solutions to combat resistance to chemotherapy. Their primary investigational drug, SCO-101, an orally administered compound, is currently progressing through Phase Ib and Phase II clinical studies with cancer patients. Another pipeline candidate, SCO-201, is undergoing preclinical assessment for its potential efficacy against solid tumors. Established in 2017, Scandion Oncology A/S maintains its headquarters in Copenhagen, Denmark.
Share Price
$0.00045794
Last synced: 2025-07-11
Market Cap
$107.51K
Change (1 day)
-36.01%
Change (1 year)
0.00%
Country
DK
Trade Scandion Oncology A/S (SCOL)

Category

Healthcare
P/E ratio for Scandion Oncology A/S (SCOL)
P/E ratio as of 2026 TTM: 0
According to Scandion Oncology A/S latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Scandion Oncology A/S from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.